Literature DB >> 34737564

Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo.

Mei-Qi Xu1,2, Yan-Li Hao1,2, Jing-Ru Wang1,2, Zhuo-Yue Li1,2, Hui Li1, Zhen-Han Feng1,2, Hui Wang1,2, Jing-Wen Wang1,2, Xuan Zhang1,2.   

Abstract

PURPOSE: Small molecule modified antitumor drug conjugate nanoparticles have the advantages of high drug loading, simple synthesis and preparation, and better biocompatibility. Due to the large demand for exogenous α-linolenic acid (ALA) by tumor cells, we synthesized α-linolenic acid-paclitaxel conjugate (ALA-PTX) and prepared α-linolenic acid-paclitaxel conjugate nanoparticles (ALA-PTX NPs), in order to obtain better tumor cellular uptake and antitumor activity in vitro and in vivo.
METHODS: We synthesized and characterized ALA-PTX, and then prepared and characterized ALA-PTX NPs. The cellular uptake, uptake pathways, intracellular behavior, in vitro and in vivo antitumor activity of ALA-PTX NPs were evaluated.
RESULTS: The size of ALA-PTX NPs was approximately 110.7±1.7 nm. The drug loading was approximately 90% (w/w) with CrEL-free and organic solvent-free characteristics. The cellular uptake of ALA-PTX NPs was significantly higher than that of PTX injection by MCF-7, MCF-7/ADR and HepG2 cells. In these three cell lines, the cellular uptake of ALA-PTX NPs at 6h was approximately 1.5-2.6 times higher than that of PTX injection. ALA-PTX NPs were ingested through clathrin-mediated endocytosis, then transferred to lysosomes, and could dissolve in cells to play an antitumor activity. The in vitro and in vivo antitumor activity of ALA-PTX NPs was confirmed in MCF-7/ADR and HepG2 cell models and tumor-bearing nude mouse models.
CONCLUSION: ALA-PTX NPs developed in our study could provide a new method for the preparation of nano-delivery systems suitable for antitumor therapy that could increase tumor cellular uptake and enhance antitumor activity.
© 2021 Xu et al.

Entities:  

Keywords:  antitumor activity; cellular uptake; α-linolenic acid; α-linolenic acid-paclitaxel conjugate; α-linolenic acid-paclitaxel conjugate nanoparticles

Mesh:

Substances:

Year:  2021        PMID: 34737564      PMCID: PMC8558831          DOI: 10.2147/IJN.S331578

Source DB:  PubMed          Journal:  Int J Nanomedicine        ISSN: 1176-9114


  29 in total

1.  Effect of XlogP and Hansen Solubility Parameters on Small Molecule Modified Paclitaxel Anticancer Drug Conjugates Self-Assembled into Nanoparticles.

Authors:  Ting Zhong; Yan-Li Hao; Xin Yao; Shuang Zhang; Xiao-Chuan Duan; Yi-Fan Yin; Mei-Qi Xu; Yang Guo; Zhan-Tao Li; Xiu-Chai Zheng; Hui Li; Xuan Zhang
Journal:  Bioconjug Chem       Date:  2018-01-29       Impact factor: 4.774

Review 2.  Intake and metabolism of omega-3 and omega-6 polyunsaturated fatty acids: nutritional implications for cardiometabolic diseases.

Authors:  Matthias B Schulze; Anne Marie Minihane; Rasha Noureldin M Saleh; Ulf Risérus
Journal:  Lancet Diabetes Endocrinol       Date:  2020-09-16       Impact factor: 32.069

Review 3.  Cancer nanomedicine: progress, challenges and opportunities.

Authors:  Jinjun Shi; Philip W Kantoff; Richard Wooster; Omid C Farokhzad
Journal:  Nat Rev Cancer       Date:  2016-11-11       Impact factor: 60.716

Review 4.  Nanocarriers as an emerging platform for cancer therapy.

Authors:  Dan Peer; Jeffrey M Karp; Seungpyo Hong; Omid C Farokhzad; Rimona Margalit; Robert Langer
Journal:  Nat Nanotechnol       Date:  2007-12       Impact factor: 39.213

5.  Cellular imaging of endosome entrapped small gold nanoparticles.

Authors:  Chang Soo Kim; Xiaoning Li; Ying Jiang; Bo Yan; Gulen Y Tonga; Moumita Ray; David J Solfiell; Vincent M Rotello
Journal:  MethodsX       Date:  2015-06-10

6.  PEGylation of lipophilic SN38 prodrug with DSPE-mPEG2000 versus cremophor EL: comparative study for intravenous chemotherapy.

Authors:  Jun Zeng; Chen Li; Xing Duan; Fuyue Liu; Anqin Li; Chunhan Luo; Li Jia; Yifang Gan; Lu Yan; Yaxin Zheng
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

7.  Antitumor activity of the bioreductive prodrug 3-(2-nitrophenyl) propionic acid-paclitaxel nanoparticles (NPPA-PTX NPs) on MDA-MB-231 cells: in vitro and in vivo.

Authors:  Xiao-Chuan Duan; Xin Yao; Shuang Zhang; Mei-Qi Xu; Yan-Li Hao; Zhan-Tao Li; Xiu-Chai Zheng; Man Liu; Zhuo-Yue Li; Hui Li; Jing-Ru Wang; Zhen-Han Feng; Xuan Zhang
Journal:  Int J Nanomedicine       Date:  2018-12-24

8.  Structural basis of omega-3 fatty acid transport across the blood-brain barrier.

Authors:  Rosemary J Cater; Geok Lin Chua; Satchal K Erramilli; James E Keener; Brendon C Choy; Piotr Tokarz; Cheen Fei Chin; Debra Q Y Quek; Brian Kloss; Joseph G Pepe; Giacomo Parisi; Bernice H Wong; Oliver B Clarke; Michael T Marty; Anthony A Kossiakoff; George Khelashvili; David L Silver; Filippo Mancia
Journal:  Nature       Date:  2021-06-16       Impact factor: 49.962

9.  Intracellular Fate of Nanoparticles with Polydopamine Surface Engineering and a Novel Strategy for Exocytosis-Inhibiting, Lysosome Impairment-Based Cancer Therapy.

Authors:  Li Ding; Xianbing Zhu; Yiling Wang; Bingyang Shi; Xiang Ling; Houjie Chen; Wenhao Nan; Austin Barrett; Zilei Guo; Wei Tao; Jun Wu; Xiaojun Shi
Journal:  Nano Lett       Date:  2017-10-27       Impact factor: 12.262

10.  Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs.

Authors:  M D Brown; C A Hart; E Gazi; S Bagley; N W Clarke
Journal:  Br J Cancer       Date:  2006-03-27       Impact factor: 7.640

View more
  1 in total

Review 1.  Nutraceutical-Based Nanoformulations for Breast and Ovarian Cancer Treatment.

Authors:  Simona Serini; Roberta Cassano; Federica Curcio; Sonia Trombino; Gabriella Calviello
Journal:  Int J Mol Sci       Date:  2022-10-10       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.